Company intelligence / Profile preview
Basking Biosciences
- Ownership
- Private
- Development stage
- Other
Overview
Basking Biosciences has completed a Phase 1 trial of its lead candidate BB-031, demonstrating safety and dose-dependent inhibition of vWF with no serious adverse events. The company is now enrolling patients in the RAISE Phase 2 proof-of-concept trial for acute ischemic stroke. Preclinical data suggest rapid recanalization of blocked vessels and reversibility with an antidote agent, BB-025. The goal is to expand the therapeutic window and eligibility for thrombolytic therapy in stroke patients beyond current standards
- Therapeutic areas
- HematologyNeurology
- Modalities
- RNA aptamers
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Basking Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Basking Biosciences.